Protara Raises $75 Million in IPO to Fund TARA‑002 Clinical Development
Protara Therapeutics raises $75 M in a public offering to fund clinical trials of its flagship TARA‑002, boosting shareholder value and accelerating rare‑disease drug development.
2 minutes to read
